Related references
Note: Only part of the references are listed.Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Immunology of Psoriasis
Michelle A. Lowes et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
The Pharmacokinetics, Pharmacodynamics, and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers
Jack G. Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
B. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
K. A. Papp et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment
Sonia A. Lamel et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2012)
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
Mary G. Boy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Therapeutic targeting of Janus kinases
Marko Pesu et al.
IMMUNOLOGICAL REVIEWS (2008)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
The JAK-STAT signaling pathway: Input and output intergration
Peter J. Murray
JOURNAL OF IMMUNOLOGY (2007)
Prevalence and treatment of psoriasis in the United Kingdom - A population-based study
JM Gelfand et al.
ARCHIVES OF DERMATOLOGY (2005)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Etanercept as monotherapy in patients with psoriasis
CL Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Regulation of JAK-STAT signalling in the immune system
K Shuai et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Share Paper
